Fig. 2
Syngeneic models of ovarian cancer differentially respond to treatment based on their genotype. 5 × 106 ID8 Trp53-/- cells with or without Brca1 or Brca2 deficiency were injected IP to make syngeneic tumour models that were treated with olaparib, anti-PD-L1 or both. Olaparib was given by 18 daily IP injections at a dose of 50 mg/kg/day; the anti-PD-L1 was administered as five daily IP injections of 200 µg anti-PD-L1 followed by one 100 µg injection every four days for a total of 11 doses. The combination group received both drugs. Mice were euthanized at humane endpoint. A-C Kaplan–Meier survival plots showing the response of all three ID8 models to olaparib monotherapy relative to vehicle control. D-E Kaplan–Meier survival plots showing the response of Brca1- and Brca2-deficient ID8 models to olaparib, anti-PD-L1 and a combination of both drugs. Log-rank (Mantel-Cox) test. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001